IE49099B1 - Cephalosporin compounds - Google Patents

Abstract

Cephalosporin antibiotics of general formula (wherein R and R, which may be the same or different, each represent a C1-4 alkyl group or R and R together with the carbon atom to which they are attached form a C3-7 cycloalkylidene group; and R<1>, R<2> and R<3>, which may be the same or different, each represents a C1-4 alkyl group) exhibit broad spectrum antibiotic activity with unusually high activity against strains of Pseudomonas organisms as well as high activity against various members of the Enterobacteriaceae. The invention also includes the non-toxic salts and non-toxic metabolically labile esters of compounds of formula (I). Also described are compositions containing the antibiotics of the invention and processes for the preparation of the antibiotics.

Description

This invention is concerned with cephalosporin compounds possessing valuable antibiotic properties.

The cephalosporin compounds in this specification are named with reference to cepham after J.Amer. Chem.

Soc., 1962, 84, 3400, the term cephem referring to the basic cepham structure with one double bond.

Cephalosporin antibiotics are widely used in the treatment of diseases caused by pathogenic bacteria in human beings and animals, and are especially useful in the treatment of diseases caused by bacteria which are resistant to other antibiotics such as penicillin compounds, and in the treatment of penicillin-sensitive patients. In many instances it is desirable to employ a cephalosporin antibiotic which exhibits activity against both gram-positive and gram-negative microorganisms, and a significant amount of research has been directed to the development of various types of broad spectrum cephalosporin, antibiotics.

Thus, for example, in our Irish Patent Specifica20 tion No. 38172 we describe a novel class of cephalosporin antibiotics containing a 7p-(a-etherified oxyimino)acylamido group, the oxyimino group having the syn configuration. This class of antibiotic compounds is characterised by high antibacterial activity against a range of gram-positive and gram-negative organisms coupled with particularly high stability to β-lactamases produced by various gram-negative organisms.

The discovery of this class of compounds has stimulated further research in the same area in attempts to find compounds which have improved properties, for example against particular classes of organisms especially gram-negative organisms.

In our Irish Patent Specification No. 42144, we describe cephalosporin antibiotics containing a 7βacylamido group of the formula R. C .CO. NH· R \ I 0.(CH2)m c (CH2)nCOOH (A) A B (wherein R is a thienyl or furyl group; R and R may vary widely and may, for example, be alkyl groups or together with the carbon atom to which they are attached form a cycloalkylidene group, and m and n are each 0 or 1 such that the sum of m and n is 0 or l), the compounds being syn isomers or mixtures of syn and anti isomers containing at least 90% of the syn isomer. The 3-position of the cephalosporin molecule may be unsubstituted or may contain one of a wide variety of possible substituents. These compounds have been found to have particularly good activity against gram-negative organisms.

Other compounds of similar structure have been developed from these compounds in further attempts to find antibiotics having improved broad spectrum antibiotic activity and/or high activity against gram-negative organisms. Such developments have involved variations in not only the 7p-acylamido group of formula (A) but also the introduction of particular groups in the 35 position of the cephalosporin molecule.

Thus, for example, South African Patent Specification 78/1870 discloses cephalosporin antibiotics wherein the 7P-acylamido side chain is inter alia a 2-(2-aminothiazol-4-yl)-2-(optionally substituted alkoxyimino)10 acetamido group and the 3-position may be substituted, for example, by the group -Ct^Y in which Y represents the residue of a nucleophile. The Specification contains, among numerous other examples, references to compounds in which the above-mentioned optionally substituted alkoxy15 imino group is a carboxyalkoxyimino or carboxycycloalkoxyimino group. With regard to the 3-position, mono- and di-alkylaminomethyl substituents are referred to, among numerous other possibilities. South African Patent Specification 78/2168 discloses in broad terms sulphoxide compounds corresponding to the sulphides described in the last-mentioned Specification.

Furthermore, Belgian Patent Specification No. 836,813 describes cephalosporin compounds wherein the group R in formula (A) above may be replaced by, for example, 2-aminothiazol-4-yl, and the oxyimino group is a hydroxyimino or blocked hydroxyimino group, e.g. a methoxyimino group. In such compounds, the 3-position of the cephalosporin molecule is substituted by a methyl group which may itself be optionally substituted by any of a large number of residues of nucleophilic compounds therein described. N-Alkylaminomethyl groups are mentioned as possible substituents in the 3-position but only mono- and di-alkylaminomethyl groups are specifically identified. In the above-mentioned Specification no antibiotic activity is ascribed to such compounds which are only mentioned as intermediates for the preparation of antibiotics described in that Specification. 39099 We have now discovered that by an appropriate selection of a small number of particular groups at the 7p-posiLion in combination with a trialkylammoniomethyl group at the 3-position, cephalosporin compounds having particularly advantageous activity (described in more detail below) against a wide range of commonly encountered pathogenic organisms may be obtained.

The present invention provides cephalosporin anti- each represent a alkyl group (preferably a straight chain alkyl group, i.e. a methyl, ethyl, n-propyl or nbutyl group and particularly a methyl or ethyl group) or s b R and R together with the carbon atom to which they are attached form a C cycloalkylidene group, preferably a J_/ 12 3 . cycloalkylidene group; and R , R and R , which may be the same or different, each represents a alkyl group, e.g. a methyl group)and non-toxic salts and non25 toxic metabolically labile esters thereof.

The compounds according to the invention are syn isomers. The syn isomeric form is defined by the configuration of the group 4909a Ra I - 0.C.C00H ^b with respect to the carboxamido group. In this Specification the syn configuration is denoted structurally as =-£— G. CO. NHIi N Ra I 0. C. COOH It will be understood that since the compounds according to the invention are geometric isomers, some admixture with the corresponding anti isomer may occur.

The invention also includes within its scope the solvates (especially the hydrates) of the compounds of formula (I). It also includes within its scope salts of esters of compounds of formula (I).

The compounds according to the present invention may exist in tautomeric forms (for example in respect of the 2-aminothiazolyl group) and it will be understood that such tautomeric forms, e.g. the 2-iminothiazolinyl form, are included within the scope of the invention. Moreover, the compounds of formula (I) depicted above may also exist in alternative zwitterionic forms, for example wherein the 4-carboxyl group is protonated and the carboxyl group in the 7-side chain is deprotonated. These alternative forms, as well as mixtures of zwitterionic forms, are J 9 ύ 9 9 included within the scope of the present invention. a b It will also be appreciated that when R and R in the above formula represent different alkyl groups, the carbon atom to which they are attached will comprise a centre of asymmetry. A centre of asymmetry will also 12 3 be present when R , R and R all represent different alkyl groups. Such compounds are diastereoisomeric and the present invention embraces individual diastereoisomers of these compounds as well as mixtures thereof.

The compounds according to the invention exhibit broad spectrum antibiotic activity. Against gram-negative organisms the activity is unusually high. This high activity extends to many β-lactamase-producing gramnegative strains. The compounds also possess high stability to β-lactamases produced by a range of gramnegative and gram-positive organisms.

Compounds according to the invention have been found to exhibit unusually high activity against strains of Pseudomonas organisms, e.g. strains of Pseudomonas aeruginosa as well as high activity against various members of the Enterobacteriaceae (e.g. strains of Escherichia coli, Klebsiella pneumoniae, Salmonella typhimurium, Shigella sonnei, Enterobacter cloacae, Serratia marcescens, Providence species, Proteus tiiirabilis, and especially indole-positive Proteus organisms such as Proteus vulgaris and Proteus morganii) and strains of Haemophilus influenzae.

The antibiotic properties of the compounds according to the invention compare very favourably with those of the aminoglycosides such as amikacin or gentamicin. In particular, this applies to their activity against strains of various Pseudomonas organisms which are not susceptible to the majority of existing commercially available antibiotic compounds. Unlike the aminoglycosides, cephalosporin antibiotics normally exhibit low toxicity in man. The use of aminoglycosides in human therapy tends to be limited or complicated by the relatively high toxicity of these antibiotics. The cephalosporin antibiotics of the present invention thus possess potentially great advantages over the aminoglycosides.

Non-toxic salt derivatives which may be formed by reaction of either or both of the carboxyl groups present in the compounds of general formula (I) include inorganic base salts such as alkali metal salts (e.g. sodium and potassium salts) and alkaline earth metal salts (e.g. calcium salts); amino acid salts (e.g. lysine and arginine salts); organic base salts (e.g. procaine, phenylethylbenzylamine, dibenzylethylenediamine, ethanolamine, diethanolamine and N-methylglycosamine salts).

Other non-toxic salt derivatives include acid addition salts, e.g. formed with hydrochloric, hydrobromic, sulphuric, nitric, phosphoric, formic and trifluoroacetic acids. The salts may also be in the form of resinates formed with, for example, a polystyrene resin or crosslinked polystyrene divinylbenzene copolymer resin containing amino or quaternary amino groups or sulphonic acid groups, or with a resin containing carboxyl groups, e.g. a polyacrylic acid resin. Soluble base salts (e.g. 099 alkali metal salts such as the sodium salt) of compounds of formula (I) may be used in therapeutic applications because of the rapid distribution of such salts in the body upon administration. Where, however, insoluble salts of compounds (I) are desired in a particular application, e.g. for use in depot preparations, such salts may be formed in conventional manner, for example with appropriate organic amines.

These and other salt derivatives such as the salts 10 with toluene-p-sulphonic and methanesulphonic acids may be employed as intermediates in the preparation and/or purification of the present compounds of formula (I), for example in the processes described below.

Non-toxic metabolically labile ester derivatives 15 which may be formed by esterification of either or both carboxyl groups in the parent compound of formula (I) include acyloxyalkyl esters e.g. lower alkanoyloxy-methyl or -ethyl esters such as acetoxy-methyl or -ethyl or pivaloyloxymethyl esters. In addition to the above ester derivatives, the present invention includes within its scope compounds of formula (i) in the form of other physiologically acceptable equivalents, i.e. physiologically acceptable compounds which, like the metabolically labile esters are converted in vivo into the parent anti25 biotic compound of formula (I).

Preferred compounds according to the present invention include those compounds of formula (i) wherein R1, R2 and R3 all represent methyl groups. Preference is also expressed for those compounds wherein R and R both represent methyl groups or together with the carbon atom to which they are attached form a cyclobutylidene group. (6R, 7R)-7-[(Z)-2-(2-Aminothiazol-4-yl)-2-(lcarboxycyclobut-l-oxyimino)acetamido]-3-trimethylammoniomethyl-ceph-3-em-4-carboxylate and its non-toxic salts and non-toxic metabolically labile esters are particularly preferred compounds according to the present invention. Other preferred compounds include (6R, 7R)-7-[(Z)-2-(2aminothiazol-4-yl)-2-(2-carboxyprop-2-oxyimino)acetamido]3-trimethylammoniomethyl-ceph-3-em-4-carboxylat e and its non-toxic salts and non-toxic metabolically labile esters.

Other compounds according to the present invention fl fo 3 include those for example wherein the groups R , R , R', 3 R and R in formula (I) are as follows:- Ra Rb R1 R2 R3 a) Alkyl groups -ch3 'C2H5GH3 ch3CH3 -C2H5 -C2H5 oh3 ch3 ch3 -ch3 -ch3C2H5 ch3CH3CH3 "C2H5C2H5 οη3CH3C2H5 •C2H5 % ch3 ch3 -cn3 -CH3C2H5C2H5CH3 -CH3 -C2h5C2H5C2H5 CH3 -C2H5 -C2H5C2H5C2H5 ch3 -ch3 -ch3C2H5 c2h5C2H5 -ch3 -C2H5C2H5G2H5C2H5 -C2H5C2H5C2H5C2H5C2H5 Ra - C - Rb 1 R1 R2 R3 b) Cycloalkylidene groups cyclopropylidene -CH3 -ch3 -ch3 cyclopentylidene -CH3 -CH3 -CH3 cyclopropylidene -c2n5 -ch3 -CH3 cyclobutylidene -C2H5 -CH3 -ch3 cyclopentylidene -G2H5 -ch3 -CH3 cyclopropylidene -C2H5 -c2«5 -CH3 cyclobutylidene -C2H5 -C2H5 -ch3 cyclopentylidene -C2H5C2H5 -CH3 cyclopropyl i’dene -C2H5 -C2H5 ’C2H5 cyclobutylidene -C2H5 -C2H5C2H5 cyclopentylidene -C2H5-G2H5 -C2H5 The compounds of formula (i) may be used for treating a variety of diseases caused by pathogenic bacteria in human beings and animals, such as respiratory tract infections and urinary tract infections.

According to another embodiment of the Invention we provide a process for the preparation of an antibiotic compound of general formula (I) as hereinbefore defined or a non-toxic salt or non-toxic metabolically labile ester thereof which comprises (A) acylating a compound of the formula (Π) >S-> 0 (a- or β-); and the dotted line bridging the 2-, 3- and 4-positions indicates that the compound is a ceph2-em or ceph-3-em compound] or a salt, e.g. an acid addition salt (formed with, for example, a mineral acid such as hydrochloric, hydrobromic, sulphuric, nitric or phosphoric acid or an organic acid such as methanesulphonic or toluene-p-sulphonic acid) or an N-silyl derivative thereof, or a corresponding compound having a group of formula - COOR^ at the 4-position [where R^ is a hydrogen atom or a carboxyl blocking group, e.g. the residue of an ester-forming aliphatic or araliphatic alcohol or an ester-forming phenol, silanol or stannanol (the said alcohol, phenol, silanol or stannanol preferably 099 containing 1-20 carbon atoms)] and having an associated anion A® such as a halide, e.g. chloride or bromide, or trifluoroacetate anion, with an acid of formula C.COOH N. 0.C.COOR (III) a b . . 5 (wherein R and R are as hereinbefore defined; R represents a carboxyl blocking group, e.g. as described for R ; and R is an amino or protected amino group) or with an acylating agent corresponding thereto; (B) reacting a compound of formula (wherein Ra, Rb, R , B and the dotted line are as herein7 7a before defined; R and R may independently represent hydrogen or a carboxyl blocking group; and X is a replaceable residue of a nucleophile, e.g. an acyloxy group such a a dichloroacetoxy group or a halogen atom such as chlorine, bromine or iodine) or a salt thereof LcrLiary amine of the formula with a (V) 3 (wherein R , R and R are as defined above); or (C) alkylating a compound of the formula 7a hereinbefore defined; and R and R both represent carboxyl blocking groups) with an alkylating agent serving to form a group of formula at the 3-position; whereafter, if necessary and/or desired in each instance, any of the following reactions, in any appropriate sequence, are carried out:2 3 i) conversion of a Δ-isomer into the desired Δ isomer, ii) reduction of a compound wherein B is>S^5 0 to 19099 form a compound wherein B is >S, iii) conversion of a carboxyl group into a non-toxic salt or non-toxic metabolically labile ester function, and iv) removal of any carboxyl blocking and/or Nprotecting groups.

In the above-described process (A), the starting material of formula (II) is preferably a compound wherein the dotted line represents a ceph-3-em compound.

Acylating agents which may be employed in the preparation of compounds of formula (I) include acid halides, particularly acid chlorides or bromides. Such acylating agents may be prepared by reacting an acid (III) or a salt thereof with a halogenating agent e.g. phosphorus pentachloride, thionyl chloride or oxalyl chloride.

Acylations employing acid halides may be effected in aqueous and non-aqueous reaction media, conveniently at temperatures of from -50 to +50°C, preferably -20 to +30°C, if desired in the presence of an acid binding agent. Suitable reaction media include aqueous ketones such as aqueous acetone, esters such as ethyl acetate, halogenated hydrocarbons such as methylene chloride, amides such as dimethylacetamide, nitriles such as acetonitrile, or mixtures of two or more such solvents.

Suitable acid binding agents include tertiary amines (e.g. triethylamine or dimethylaniline), inorganic bases (e.g. calcium carbonate or sodium bicarbonate), and oxiranes such as lower 1,2-alkylene oxides (e.g. ethylene oxide or propylene oxide) which bind hydrogen halide liberated in the acylation reaction.

Acids of formula (III) may themselves be used as acylating agents in the preparation of compounds of formula (I). Acylations employing acids (ill) are desirably conducted in the presence of a condensing agent, for example a carbodiimide such as Ν,Ν’-dicyclohexylcarbodiimide or N-ethyl-Ν'-y-dimethylaminopropylcarbodiimide; a carbonyl compound such as carbonyldiimidazole; or an isoxazolium salt such as N-ethyl-5-phenylisoxazolium perchlorate.

Acylation may also be effected with other amideforming derivatives of acids of formula (III) such as, for example, an activated ester, a symmetrical anhydride or a mixed anhydride (e.g. formed with pivalic acid or with a haloformate, such as a lower alkylhaloformate). Mixed anhydrides may also be formed with phosphorus acids (for example phosphoric or phosphorous acids), sulphuric acid or aliphatic or aromatic sulphonic acids (for example toluene-p-sulphonic acid). An activated ester may conveniently be formed in situ using, for example, 1-hydroxybenzotriazole in the presence of a condensing agent as set out above. Alternatively, the activated ester may be preformed.

Acylation reactions involving the free acids or their above-mentioned amide-forming derivatives are desirably effected in an anhydrous reaction medium, e.g. methylene chloride, tetrahydrofuran, dimethylformamide or acetonitrile.

If desired, the above acylation reactions may be carried out in the presence of a catalyst such as 4-dime thylaminopyridine.

The acids of formula (III) and acylating agents corresponding thereto may, if desired, be prepared and employed in the form of their acid addition salts. Thus, for example, acid chlorides may conveniently be employed as their hydrochloride salts, and acid bromides as their hydrobromide salts.

The amine compound of formula (V) may act as a nucleophile to displace a wide variety of substituents X from the cephalosporin of formula (IV). To some extent the facility of the displacement is related to the pK Q. of the acid HX from which the substituent is derived.

Thus atoms or groups X derived from strong acids tend, in general, to be more easily displaced than atoms or groups derived from weaker acids. The facility of the displacement is also related, to some extent, to the precise identities of the alkyl groups in the compound of formula (V).

The displacement of X by the amine of formula (V) may conveniently be effected by maintaining the reactants in solution or suspension. The reaction is advantageously effected using from 1 to 20, preferably 1 to 4, moles of the amine (V).

Nucleophilic displacement reactions may conveniently be carried out on those compounds of formula (IV) wherein the substituent X is a halogen atom or an acyloxy group for example as discussed below.

Acyloxy groups Convenient starting materials for use in the nucleophilic displacement reaction with the amine of formula (V) include compounds of formula (IV) in which X is the residue of a substituted acetic acid e.g. chloroacetic acid, dichloroacetic acid and trifluoroacetic acid.

The substituent X may also be derived from formic acid, a haloformic acid such as chloroformic acid, or a carbamic acid.

When using a compound of formula (IV) in which X represents a substituted acetoxy group, it is generally desirable that the group R? in formula (IV) should be a hydrogen atom and that B should represent }s. In this case, the reaction is advantageously effected in an aqueous medium, preferably at a pH of 5 to 8, particularly 5.5 to 7.

The above-described process employing compounds of formula (IV) in which X is the residue of a substituted acetic acid may be carried out as described in Patent Specification No. 32293 .

When using compounds of formula (IV) in which X is an acyloxy group, the reaction is conveniently effected at a temperature of -20° to +80°C, preferably 0° to +50°C.

Halogens Compounds of formula (IV) in which X is a chlorine, bromine or iodine atom can advantageously be used as starting materials in the nucleophilic displacement reac5 tion with the amine of formula (V). When using compounds of formula (IV) in this class, B may represent>S—>0 and R? may represent a carboxyl blocking group. The reaction is conveniently effected in a non-aqueous medium which preferably comprises one or more organic solvents, advantageously ethers, e.g. dioxan or tetrahydrofuran, esters, e.g. ethyl acetate, amides, e.g. formamide and N,N-dimethylformamide, and ketones, e.g. acetone.

Other suitable organic solvents are described in more detail in our Irish Patent Specification No. 35152.

The reaction medium should be neither extremely acidic nor extremely basic. In the case of reactions carried 7 7a out on compounds of formula (IV) in which R and R are carboxyl blocking groups the 3-trialkylammoniomethyl product will be formed as the corresponding halide salt which may, if desired, be subjected to one or more ion exchange reactions to obtain a salt having the desired anion.

When using compounds of formula (IV) in which X is a halogen atom as described above, the reaction is conveniently effected at a temperature of -10° to +50°C, preferably +10 to +30’C.

In process (C) above, the 3-di-C^_^alkylaminomethyl compound of formula (VI) is advantageously reacted with a 3 3 alkylating agent of the formula R Y wherein R is as defined above and Y is a leaving group such as a halogen atom (e.g. iodine, chlorine or bromine) or a hydrocarbylsulphonate (e.g. mesylate or tosylate) group, or R Y represents dimethyl sulphate. The alkylation reaction is preferably carried out at a temperature in the range of 0 to 60°C, advantageously 20 to 30°C. The reaction may be conveniently effected in an inert solvent such as an ether e.g. tetrahydrofuran, an amide, e.g. dimethylformamide, or a halogenated hydrocarbon, e.g. dichloromethane. Alternatively, where the alkylating agent is liquid under the reaction conditions, this agent can itself serve as a solvent.

The compound of formula (VI) used as starting material in process (C) may be prepared for example by reaction of a compound of formula (IV) (as defined above) with a secondary amine of formula HN XR2 (VII) 2 (wherein R and R are as defined above) in an analogous manner to the nucleophilic displacement reaction described with respect to process (B). This reaction is preferably carried out in the presence of an acid scavenging agent. The amine itself may act as an acid scavenging agent.

The reaction product may be separated from the reaction mixture, which may contain, for example, unchanged cephalosporin starting material and other substances, by a variety of processes including recrystallisa tion, ionophoresis, column chromatography and use of ionexchangers (for example by chromatography on ion-exchange resins) or macroreticular resins.

-Cephalosporin ester derivatives obtained in accordance with the process of the invention may be con3 verted into the corresponding -derivative by, for 2 example, treatment of the Δ -ester with a base such as pyridine or triethyiamine.

A ceph-2-em reaction product may also be oxidised to yield the corresponding ceph-3-em 1-oxide, for example by reaction with a peracid, e.g. peracetic or m-chloroperbenzoic acid; the resulting sulphoxide may, if desired, subsequently be reduced as described hereinafter to yield the corresponding ceph-3-em sulphide.

Where a compound is obtained in which B is J>S —0 this may be converted to the corresponding sulphide by, for example, reduction of the corresponding acyloxysulphonium or alkoxysulphonium salt prepared in situ by reaction with e.g. acetyl chloride in the case of an acetoxysulphonium salt, reduction being effected by, for example, sodium dithionite or by iodide ion as in a solution of potassium iodide in a water-miscible solvent e.g. acetic acid, acetone, tetrahydrofuran, dioxan, dimethylformamide or dimethylacetamide. The reaction may be effected at a temperature of from -20° to +50°C.

Metabolically labile ester derivatives of the compounds of formula (I) may be prepared by reacting a compound of formula (I) or a salt or protected derivative thereof with an appropriate esterifying agent such as an acyloxyalkyl halide (e.g. iodide) conveniently in an inert organic solvent such as dimethylformamide or acetone, followed, where necessary, by removal of any protecting groups.

Base salts of the compounds of formula (I) may be formed by reacting an acid of formula (l) with the appropriate base. Thus, for example, sodium or potassium salts may be prepared using the respective 2-ethylhexanoate or hydrogen carbonate salt. Acid addition salts may be prepared by reacting a compound of formula (I) or a metabolically labile ester derivative thereof with the appropriate acid.

Where a compound of formula (I) is obtained as a mixture of isomers, the syn isomer may be obtained by, for example, conventional methods such as crystallisation or chromatography.

For use as starting materials for the preparation of compounds of general formula (I) according to the invention, compounds of general formula (III) and acid halides and anhydrides corresponding thereto in their syn isomeric form or in the form of mixtures of the syn isomers and the corresponding anti isomers containing at least 90% of the syn isomer are preferably used.

Acids of formula (III) (provided that Ra and Rb together with the carbon atom to which they are attached do not form a cyclopropylidene group) may be prepared by etherification of a compound of formula C.COOR8 II (VIII) OH 8 (wherein R is as hereinbefore defined and R represents a carboxyl blocking group), by reaction with a compound of general formula T is halogen such as chloro, bromo or iodo; sulphate; or sulphonate such as tosylate), followed by removal of the g carboxyl blocking group R . Separation of isomers may be effected either before or after such etherification. The etherification reaction is generally carried out in the presence of a base, e.g. potassium carbonate or sodium hydride, and is preferably conducted in an organic solvent, for example dimethylsulphoxide, a cyclic ether such as tetrahydrofuran or dioxan, or an Ν,Ν-disubstituted amide such as dimethylformamide. Under these conditions the configuration of the oxyimino group is substantially unchanged by the etherification reaction. The reaction should be effected in the presence of a base if an acid addition salt of a compound of formula (VIII) is used.

The base should be used in sufficient quantity to neutralise rapidly the acid in question.

Acids of general formula (ill) may also be prepared by reaction of a compound of formula '-*- GO. COOR8 (X) 8 z (wherein R and R are as hereinbefore defined) with a compound of formula R * 5 H_N. 0. C. GOOR^ 2 (XI) (wherein Ra, Rb and R^ are as defined above), followed by θ removal of the carboxyl blocking group R , and where necessary by the separation of syn and anti isomers.

The last-mentioned reaction is particularly applicable to the preparation of acids of formula (III) wherein a b R and R together with the carbon atom to which they are attached form a cyclopropylidene group. In this case, the relevant compounds of formula (XI) may be prepared in conventional manner, e.g. by means of the synthesis described in Belgian PatentSpecification No. 866,422 for the preparation of t-butyl 1-amino-oxycyclopropane carboxylate.

The acids of formula (III) may be converted to the corresponding acid halides and anhydrides and acid addition salts by conventional methods, for example as described hereinabove.

Where X is a halogen (i.e. chlorine, bromine or iodine) atom in formula (IV), ceph-3-em starting compounds may be prepared in conventional manner, e.g. by halogenation of a 7p-protected amino-3-methylceph-3-em-4-carboxylic acid ester Ιβ-oxide, removal of the 7p-protecting group, acylation of the resulting 7β-βπιϊηο compound to form the desired 7β-acylamido group, e.g. in an analogous manner to process (A) above, followed by reduction of the Ιβ-oxide group later in the sequence. This is described in British Patent No. 1,326,531. The corresponding ceph-2em compounds may be prepared by the method of Dutch published Patent Application No. 6,902,013 by reaction of a 3-methylceph-2-em compound with N-bromosuccinimide to yield the corresponding 3-bromomethylceph-2-em compound.

Where X in formula (IV) is an acetoxy group, such starting materials may be prepared for example by acylation of 7-aminocephalosporanic acid, e.g. in an analogous manner to process (A) above. Compounds of formula (IV) in which X represents other acyloxy groups can be prepared by acylation of the corresponding 3-hydroxymethyl compounds which may be prepared for example by hydrolysis of the appropriate 3-acetoxymethyl compounds, e.g. as described in British Patent Specifications Nos. 1,474,519 and 1,531,212.

T..e starting materials of formula (ll) are new compounds. These compounds may be prepared in conventional manner, for example, by deprotecting a corresponding protected 7p-amino compound in conventional manner e.g. using PCI,-.

It should be appreciated that in some of the above transformations it may be necessary to protect any sensitive groups in the molecule of the compound in question to avoid undesirable side reactions. For example, during any of the reaction sequences referred to above it may be necessary to protect the NH^ group of the aminothiazolyl moiety, for example by tritylation, acylation (e.g. chloroacetylation), protonation or other conventional method. The protecting group may thereafter be removed in any convenient way which does not cause breakdown of the desired compound, e.g. in the case of a trityl group by using an optionally halogenated carboxylic acid, e.g. acetic acid, formic acid, chloroacetic acid or trifluoroacetic acid or using a mineral acid, e.g. hydrochloric acid or mixtures of such acids, preferably in the presence of a protic solvent such as water or, in the case of a chloroacetyl group, by treat20 ment with thiourea.

Carboxyl blocking groups used in the preparation of compounds of formula (I) or in the preparation of necessary starting materials are desirably groups which may readily be split off at a suitable stage in the reaction sequence, conveniently at the last stage. It may, however, be convenient in some instances to employ non-toxic metabolically labile carboxyl blocking groups such as acyloxy-methyl or -ethyl groups (e.g. acetoxy27 methyl or -ethyl or pivaloyloxymethyl) and retain these in the final product to give an appropriate ester derivative ο I a compound of formula (I).

Suitable carboxyl blocking groups are well known 5 in the art, a list of representative blocked carboxyl groups being included in out Patent Specification No. 38172. Preferred blocked carboxyl groups include aryl lower alkoxycarbonyl· groups such as £-methoxybenzyloxycarbonyl, £-nitrobenzyloxycarbonyl and diphenylmethoxycarbonyl; lower alkoxycarbonyl groups such as Jt-butoxycarbonyl; and lower haloalkoxycarbonyl groups such as 2,2,2-trichloroethoxycarbonyl. Carboxyl blocking group(s) may subsequently be removed by any of the appropriate methods disclosed in the literature; thus, for example, acid or base catalysed hydrolysis is applicable in many cases, as are enzymically-catalysed hydrolyses.

The following Examples illustrate the invention.

All temperatures are in °C. 'Petrol' means petroleum ether (b.p. 40-60°).

Preparation 1 Ethyl (Z)-2-(2-aminothiazol-4-yl)-2-(hydroxyimino)acetate To a stirred and ice-cooled solution of ethyl acetoacetate (292 g) in glacial acetic acid (296 ml) was added a solution of sodium nitrite (180 g) in water (400 ml) at such a rate that the reaction temperature was maintained below 10°C. Stirring and cooling were continued for about 30 min., when a solution of potassium chloride (160 g) in water (800 ml) was added. The resulting mixture was stirred for one hour. The lower oily 3C phase was separated and the aqueous phase was extracted with diethyl ether. The extract was combined with the 49098 oil, washed successively with water and saturated brine, dried, and evaporated. The residual oil, which solidified on standing, was washed with petrol and dried in vacuo over potassium hydroxide, giving ethyl (Z)-2-(hydroxyimino)-3-oxobutyrate (309 g).

A stirred and ice-cooled solution of ethyl (z)-2(hydroxyimino)-3-oxobutyrate (150 g) in dichloromethane (400 ml) was treated dropwise with sulphuryl chloride (140 g). The resulting solution was kept at room temperature for 3 days, then evaporated. The residue was dissolved in diethyl ether, washed with water until the washings were almost neutral, dried, and evaporated. The residual oil (177 g) was dissolved in ethanol (500 ml) and dimethylaniline (77 ml) and thiourea (42 g) was added with stirring. After two hours, the mixture was filtered and the residue washed with ethanol and dried to give the title compound (73 g); m.p. 188J (decomp.). Preparation 2 Ethyl (Z)-2-hydroxyimino-2-(2-tritylaminothiazol-4-yl)acetate, hydrochloride Trityl chloride (16.75 g) was added portionwise over 2 hours to a stirred and cooled (-30J) solution of the product of Preparation 1 (12.91 g) and triethylamine (8.4 ml) in dimethylformamide (28 ml). The mixture was allowed to warm to 15° over one hour, stirred for a further 2 hours and then partitioned between water (500 ml) and ethyl acetate (500 ml). The organic phase was separated, washed with water (2 x 500 ml) and then shaken with IN HCl (500 ml). The precipitate was collected, washed successively with water (100 ml), ethyl acetate (200 ml) and ether (200 ml) and dried in vacuo to provide the title compound as a white solid (16.4 g); m.p. 1-4 to )563 (decomp.).

Preparation 5 Ethyl (Z)-2-(2-t-butoxycarbonylprop-2-oxyimino)-2-(25 tritylaminothiazol-4-yl)acetate Potassium carbonate (34· 6 g) and t-butyl 2-bromo2-methylpropionate (24.5 g) were added to a stirred solution under nitrogen of the product of Preparation 2 (49.4 g) in dimethylsulphoxide (200 ml) and the mixture was stirred at room temperature for 6 hours. The mixture was poured into water (2 l), stirred for 10 mins., and filtered. The solid was washed with water and dissolved in ethyl acetate (600 ml). The solution was washed successively with water, 2N hydrochloric acid, water, and saturated brine, dried, and evaporated. The residue was recrystallised from petrol to give the title compound (34 g), m.p. 123.5 to 125°.

Preparation 4 (Z)-2-(2-t-Butoxycarbonylprop-2-oxyimino)-2-(2-trityl20 amlnothiazol-4-yl)acetic acid The product of Preparation 3 (2 g) was dissolved in methanol (20 ml) and 2N sodium hydroxide (3.3 ml) was added. The mixture was refluxed for 1.5 hours and then concentrated. The residue was taken up in a mixture of water (50 ml), 2N hydrochloric acid (7 ml), and ethyl acetate (50 ml). The organic phase was separated, and the aqueous phase extracted with ethyl acetate. The organic solutions were combined, washed successively with water and saturated brine, dried and evaporated. The residue was recrystallised from a mixture of carbon Letrachloride and petrol to give the title compound (l g) , m.p. 152 to 156° (decomp.).

Preparation 5 Ethyl (Z)-2-(2-trityIaminothiazol-4-yl)-2-(1-t-butoxycarbonylcyclobut-l-oxyimino) acetate The product of Preparation 2 (55.8 g) was stirred under nitrogen in dimethylsulphoxide (400 ml) with potassium carbonate (finely ground, 31.2 g) at room temperature. After 30 minutes, t-butyl 1-bromocyclobutanecarboxylate (29.2 g) was added. After 8 hours further potassium carbonate (31.2 g) was added. More potassium carbonate (6 x 16 g portions) was added during the next three days and further t-butyl 1-bromocyclobutanecarboxylate (3.45 g) was added after 3 days. After 4 days in all, the mixture was poured into ice-water (ca. litres) and the solid was collected by filtration and washed well with water and petrol. The solid was dissolved in ethyl acetate and the solution washed with brine (twice), dried with magnesium sulphate and evaporated to a foam. This foam was dissolved in ethyl acetatepetrol (l:2) and filtered through silica gel (500 g). Evaporation gave the title compound (60 g) as a yellow foam, j (GHBro) 3400 (NH) and 1730 cm (ester). ’ max 3 Preparation 6 (Z)-2-(1-t-Butoxycarbonylcyclobut-l-oxyimino)-2-(2-tritylaminothiazol-4-yl) acetic acid A mixture of the product of Preparation 5 (3.2 g) and potassium carbonate (1.65 g) was refluxed in methanol 0 9 9 ( HO ml) and water (20 ml) for 9 hours and the mixture was cooled Lo room temperature. The mixture was concentrated and the residue partitioned between ethyl acetate and water, to which was added 2N HCl (12,,2 ml). The organic phase was separated and the aqueous phase extracted with ethyl acetate. The combined organic extracts were washed with saturated brine, dried and evaporated to give the title compound (2.3 g); χ •t ot — rnax (ethanol) 265 nm (E, ° 243). lcm Example 1 a) Diphenylmethyl (IS,6R,7R)-3-Bromomethyl-7-[(Z)-2-(2-tbutoxycarbonylprop-2-oxvimino)-2-(2-tritylanu.nothiazol-4yl)acetamido]ceph-3-em-4-carboxylate, l-0xide A solution of the product of Preparation 4 (0.526 g) in dry tetrahydrofuran (6 ml) was treated successively with 1-hydroxybenztriazoie monohydrate (0.141 g) and Ν,Ν'-dicyclohexylcarbodiimide (0.198 g) in tetrahydrofuran (4 ml). The developing suspension was stirred for 30 minutes at 23° and then filtered. A solution of diphenyl20 methyl (IS,6R,7R)-7-amino-3-bromomethylceph-3-em-4carboxylate, 1-oxide (0.427 g) in dichloromethane (260 ml) was treated at 23° with the above filtrate. The solution was stirred for 18 hours at 20° to 25°, evaporated to dryness, then the residue was dissolved in dichloromethane and washed successively with saturated aqueous sodium bicarbonate, water and brine, then dried and evaporated in vacuo to a foam (1.01 g).

This foam was purified by chromatography on preparative silica plates using toluene:ethyl acetate:acetic acid = 190:50:2.5 as eluant. The purified product was isolated as a foam which was dissolved in ethyl acetate (5 ml) and precipitated from petrol (200 ml) to give the title compound (0.69 g) as a colourless powder; λ_ (EtOH) -- „max 268 nm (£^^,182) with an inflection at 242 nm EiJm23°)> v (*Nujol)3375 (NH), 1805 (β-lactam), 1730 (CO R) and ftlclX ί 1688 and 1515 cm' (CONH). b) Diphenylmethyl (lS,6R,7R)-7-f(Z)-2-(2-t-butoxycarbonyl10 prop-2-oxyimino)-2-(2-tritylaimnothiazol-4-yl)-acetamido ] trimethylanmoniomethylceph-3-em-4-carboxylate, l-0xide, Bromide Salt The product of stage a) (0.154 g), alumina-dried tetrahydrofuran (0.3 ml) and anhydrous trimethylamine in dry tetrahydrofuran (0.155 g of trimethylamine in 1 ml of solution) (0.065 ml) were stirred at 24° for 1 hour. The reaction mixture was added dropwise to well-stirred ether (220 ml) and the resulting suspension was stirred vigorously for 10 minutes. The solid was filtered off, washed with ether and dried in vacuo to give the title 21 compound (0.131 g) m.p. 158° to 1783 (decomp.); [α]θ + 11° (c 0.53, CHC13).

*Nujol is a Trade Mark 0 9 9 c) Diphenylmethyl (6R,7R)-7-(~ (Z)-2-(2-t-Butoxycarbonylprop-2-oxyimino)-2-(2-tritylamino thiazol-4-yl)acetamido]3-trimethylammoniomethylceph-3-em-4-carboxylate, Iodide Sait The product of stage b) (1.87 g) and acetone (4.7 ml) were stirred at -10° as a solution. Dry, powdered potassium iodide (1.14 g) was added and the mixture was stirred at -10° for 2 minutes. Dry, powdered potassium iodide (1.14 g) followed by acetyl chloride (0.25 ml) were added and the vigorously stirred mixture was allowed to warm to 0° over 20 minutes. The mixture was stirred at 0J to +2° for 1 hour. The mixture was added dropwise to a stirred solution of sodium metabisulphite (0.850 g) in water (47 ml). The resulting solid was filtered off, washed with water and dried in vacuo over phosphorus pentoxide to give a solid (1.939 g). The above procedure was repeated using the solid (1.87 g), acetone (4.7 ml), dry powdered potassium iodide (1.14 g), acetyl chloride (0.25 ml) and a reaction time at 0° to +2° of 25 minutes. This gave the title compound (1.951 g) as a solid, m.p. 142° to 17β; [a]2-16° (c 0.38, CHCip. d) Diphenylmethyl (6R,7R)-7~r(Z)-2-(2-t-Butoxvcarbonvlprop-2-oxyimino)-2-(2-tritylaminothiazol-4-yl)-acetamido]3-trimethylammoniomethylceph-3-em-4-carboxylate, Trifluoro25 acetate Salt The product of stage c) (1.826 g) was dissolved in acetone:ethanol = 9:1 and chromatographed on *Deacidite FF SRA 62 ion exchange resin (strong anion exchange resin) trifluoroacetate form. The column was eluted with the *Deacidite is a Trade Mark above solvent mixture. A forerun of 20 ml was discarded and the next 250 ml were evaporated in vacuo immediately to give the title compound (1.595 g) as a red-brown foam, e) (6R,7R)-7-r(Z)-2-(2-Aminothiazol-4-yl)-2-(2-carboxyprop-2-oxyimino)acetamido]-3-trimethylammoniomethylceph3-em-4-carboxylate The product of stage d) (1.37 g), anisole (1.37 ml) and trifluoroacetic acid (5.5 ml) were swirled together at 25° for 1¾ minutes, when a solution was formed, and then for a further 1 minute. The volatile material was evaporated off and the residue was azeotroped with toluene (twice). The gum was dissolved in acetone (10 ml) and precipitated into petrol (500 ml). The brown solid was filtered off, washed with petroleum ether and dissolved in acetone. The solution was evaporated to a foam (1.117 g).

The foam (1.117 g), anisole (0.25 ml) and trifluoroacetic acid (5 ml) were swirled together at 28° for 5 minutes. The volatile material was removed and the residue was azeotroped with toluene (twice). The resulting brown oil was precipitated with acetone (10 ml) and 40° to 60’ petroleum ether (500 ml) to give a solid (1.066 s)· The solid (0.2 g) was dissolved in trifluoroacetic acid:water = 1:1 (2 ml) and the solution was stirred at 28° for 30 minutes. The mixture was evaporated to dryness and the resulting gum was dissolved in water (10 ml). The cloudy solution was filtered, the residue was washed with water (10 ml, 5 ml) and the filtrate was freezedried to give a foam, (0.17 g). The foam was triturated with ether, the solid obtained was filtered rapidly and dried in vacuo to give the title compound (0.148g) as a solid associated with 1.8 moles of trifluoroacetic acid; [a]22 + 120° (c 0.3; EtOH:H20 = 1:1); Xinf (pH6 buffer) 230 nm (ε 17,000), λ inf 260 nm (ε 10,200).

Example 2 a) Diphenylmethyl· (lS,6R,7R)-3-Bromomethyl-7-r(Z)-2(l-t-butoxycarbonylcyclobut-l-oxyimino)-2-(2-tritylaminociiiazol-4-yl·) acetamido ]-cep?i-3-em-4-carboxylate, 1 Oxide A stirred solution of the product of Preparation 6 (1.167 g) in tetrahydrofuran (15 ml) was treated successively with 1-hydroxybenztriazole hydrate (0.337 g) and Ν,Ν'-dicyclohexylcarbodiimide (0.495 g) for 30 minutes at 22°.

Filtration afforded a solution of the activated ester which was added to a solution of diphenylmethyl (lS,6R,7R)-7-amino-3-bromomethylceph-3-em-4-carboxylate 1-oxide (0.95 g) in dichloromethane (550 ml).- The solution was stirred for 16 hours then evaporated to dryness. A solution of the residue in dichloromethane was washed successively with aqueous sodium bicarbonate, and brine, and then dried and evaporated to a foam (2.2 g) which was purified by preparative thin-layer chromatography (using toluene:ethyl acetate:acetic acid = 40:10:1 for development) to give the title compound (1.4 g) with -,γ λ (EtOH) 266 nm (E. 192) and an inflection at 242.5 nm max 1cm (eJ% 224), v (Nujol) 3360 (NH), 1805 (β-lactam), i.cxn max η 1730 (C02R) and 1689 and 1520 cm (CONH). b) Diphenylmethyl (lS,6R,7R)-7-[(Z)-2-(l-t-Butoxycarbonylcyclobut-1-oxyimino)-2-(2-tritylaminothiazol-4-yl)acetamido]-3-trimethylammoniomethylceph-3-em-4-carboxylate, 1-Oxide, Bromide Salt The product of stage a) (1.2 g), alumina-dried tetrahydrofuran (2.5 ml) and anhydrous trimethylamine in dry tetrahydrofuran [0.49 ml of a solution of trimethylamine (0.155 g) in tetrahydrofuran (l ml)] were stirred at 24° for 30 minutes. The reaction mixture was added dropwise to stirred ether (900 ml) and the resulting suspension was stirred vigorously for 10 minutes. The solid was filtered off, washed with ether and dried in vacuo to give the title compound (1.16 g), m.p. 156° to 170° (decomp); [α]^ + (£ θ·48, CHCl^). c) Diphenylmethyl (6R,7R)-7~r(Z)-2-(l-t-Butoxycarbonylcyclobut-l-oxvimino)-2-(2-tritylaminothiazol-4-yl)acetamido]-3-trimethylammoniomethylceph-3-em-4-carboxylate, Iodide Salt The product of stage b) (1.05 g) and acetone (2.6 ml) were stirred as a solution at -10°. Dry, powdered potassium iodide (0.625 g) was added and the mixture was stirred at -10" for 2 minutes. Further dry, powdered potassium iodide (0.625 g) was added followed by acetyl chloride (0.14 ml). The stirred mixture was allowed to warm to 0° and it was stirred at 0° to +2° for % hour.

The mixture was added dropwise to a stirred soluLion of sodium metabisulphite (0.465 g) in water (26 ml). The resulting solid was filtered off, washed with water and dried in vacuo over phosphorus pentoxide to give a solid (1.072 g). The above procedure was repeated using the solid (1.072 g), acetone (2.6 ml), dry, powdered potassium iodide (0.625 g), and acetyl chloride (0.14 ml) to give the title compound (1.131 g) as a solid, m.p. 133 to 170° (decomp) [a]^-33° (c 0.6, CHCl^). d) (6R,7R)-7-r (Ζ)-2-(2-Απύ.ηοί1ίίηζο1-4-νΐ)-2-(ΐ-οηι1)οχνcyclobut-l-oxyimino)acetamido]-3-trimethylammoniomethylc eph-3-em-4-carboxy late The product of stage c) (0.2 g) was wetted with anisole (0.2 ml) and trifluoroacetic acid (0.8 ml) was added. An immediate precipitate was formed and the suspension was swirled for 2 minutes at ca 23° when the precipitate became gummy. The mixture was evaporated to dryness and the residue was triturated with ether to give a solid which was wetted with anisole (0.035 ml) and tri20 fluoroacetic acid (4 ml) was added. A very fine precipitate formed and the suspension was swirled at 23° for 15 minutes. The mixture was evaporated to a gum which was triturated with ether to give the title compound (0.091 g) as a solid, associated with 1 mole of trifluoroacetic 22 acid and 0.4 mole of hydrogen iodide, [a]+ 45° (c 0.22, ethanol:water = 1:1), λ inf (pH 6 buffer) 257.5 nm (eJ% 240), λ inf 296 nm (eJJ 115).

Example- 3 a) Diphenylmethyl (lSi6R,7R)-7-L(Z)-2-(l-t-Butoxycarbonylcyclobut-l-oxyimino)-2-(2-tritylaminothiazol-4-yl)acetamido]-3-dimethylaminomethylceph-3-em-4-carboxylate, 15 Oxide The product of Example 2(a) (0.52 g) in dry tetrahydrofuran (2 ml) was treated with a solution of dimethylamine in ethanol (33% w/w; 0,20 ml). After 15 minutes at 21°, the mixture was partitioned between ethyl acetate (25 ml) and water (25 ml). The aqueous layer was extracted with more ethyl acetate (25 ml) and the total organic solution was washed with water (2x50 ml) and dried (Na2S0^) and evaporated to a foam (0.498 g). The crude product was purified by preparative thin-layer chroma15 tography on silica-gel plates (2mm thick) eluted with ethyl acetate. The main band, R^ 0.4 yielded a foam (0.331 g) which was dissolved in ethyl acetate (2 ml) and added slowly to stirred petrol (50 ml). The precipitate was filtered off and washed with petrol and dried in vacuo to give the title compound (0.224 g) as a solid, [α]ρ-21° (c 0.87%, CHCl ), Xinf(EtOH) 245 nm (eJ^225), 260 (eJ^IO) and 305 nm (E^0 57). lcm b) Diphenylmethyl (lS,6R,7R)-7-L(Z)-2-(l-t-Butoxycarbonylcyclobut-l-oxyimino)-2-(2-tritylaminothiazol-4-yl)25 acetamido]-3-trimethylammoniomethylceph-3-em-4-carboxylate, 1-oxide, Iodide Salt The product from stage (a) (0.201 g) was dissolved in iodomethane (1 ml) and the solution was left to stand at 21° for 1¾ hours. Diethyl ether (20 ml) was added, and the precipitate was triturated and then filtered off and washed with ether and dried in vacuo to give the title compound (0.199 g) as a solid, [α]^+10° (c 0.87%, CHCl^), ^^^(EtOH) 260 nm (^^160), 265 nm (^^154) and 305 nm (E?/° 64) with a λ at 394 nm (E?·4 43). lcm max 1cm Example 4 a) Diphenylmethyl (IS,6R,7R)-7-Formamido-3-trimethylammoniomethylceph-3-em-4-carboxylate, 1-oxide, Bromide Salt A solution of diphenylmethyl (lS,6R,7R)-3-bromomethyl7-formamidoceph-3-em-4-carboxylate, 1-oxide (1.01 g) in dry N,N-dimethylformamide (3 ml) was treated with a solution (0.8 ml) of anhydrous trimethylamine in tetrahydrofuran (0.155 g of trimethylamine per ml of solution) and the solution was stirred at 21° for 15 minutes. Ether (10 ml) was added and the supernatant solution was discarded. Trituration of the oily residue with ether (ca. 15 ml) gave a precipitate which was filtered off, washed with ether and dried rapidly in vacuo to give the title compound (1.002 g) as a solid m.p. 140° to 150° (with decomp), v (Nujol) ca. 3400 (NH), 1798 (β-lactam), max — i 1680 (C=O of HCONH), 1732 (CO2R), and 1035 cm (sulphoxide) . b) Diphenylmethyl (lS,6R,7R)-7-Amino-3-triinethylaminonio" methylceph-3-em-4-carboxylate, l-Oxide, Hydrochloride and Bromide Salts A mixture of the product of stage (a) (0.562 g) in methanol (5 ml) was stirred at 0° and treated, dropwise, with phosphoryl chloride (0.28 ml) over 10 minutes. The mixture was stirred at 0° for 2 hours to precipitate a 49099 ' buff solid. Ether (15 ml) was added to the stirred mixture then the precipitate was filtered off and washed successively with ether and ethyl acetate and dried in vacuo to give the title compound (0.479 g) as a solid, λ (EtOH) 280 nm 117), v (Nujol) 3700 to 2200 (&L·), 1807 (0-lactam) and 1734 cm-1 (C02R). c) Diphenylmethyl (IS,6R,7R)-7-L(Z)-2-(2-t-Butoxycarbonylprop-2-oxyimino)-2-(2-tritylaminothiazoi-4-yl)acetamido]3-trimethylammpniomethylceph-3-em-4-carboxylate, 1-Oxide, Bromide Salt Phosphorus pentachloride (0.11 g), in dry dichloromethane (10 ml) at 0° was treated with the product of Preparation 4 and the solution was stirred at 0° for 35 minutes. Triethylamine (0.16 ml) was added and stirring was continued at 0° for 5 minutes. The solution was then added dropwise, over 5 minutes to a vigorously stirred suspension of the product of stage (b) (0.286 g) in dichloromethane (15 ml) at 0°. The suspension was stirred at 0° for 15 minutes, 20° for 2 hours and was then allowed to stand at 4° overnight.

The mixture was partitioned between ethyl acetate (100 ml) and water (100 ml) and the emulsion was clarified by filtration. The organic phase was washed with water (100 ml) then dried over sodium sulphate and evaporated to a foam. A solution of this foam in ethyl acetate (4 ml) was added dropwise to stirred petrol (120 ml). The precipitate was filtered off and washed with petrol and dried in vacuo to give the crude product (0.363 g) as a solid. Some solid remained on the sinter; this was dissolved in ethyl acetate and the solution evaporated to a gum (0.019 g). The above combined products (0o33 g) were stirred with ethyl acetate (20 ml) for 15 minutes with trituration of the precipitate. The stirred mixture was slowly diluted with ether (20 ml) and, after a further 10 minutes, the solid was filtered off and washed with ether and dried in vacuo to give the title tv 17 305 nm (E, 68) with λ at 385 nm (Et'0 32), v (CHBr,) lcm max 1cm ' max 3 3670 (water), 3600 to 2500 (NH), 1804 (β-lactam), 1730 (C02R), 1680 and 1513 cm’1 (CONH).

The title compound may be converted into (6R,7R)7-[(Z)-2-(2-Aminothiazol-4-yl)-2-(2-carboxyprop-2-oxyimino) 15 acetamido ]-3-trimethylamitioniomethylceph-3~ein"4-carboxylate as described in Example 1. 4-9099 The antibiotic compounds of the invention may be formulated for administration in any convenient way, by analogy with other antibiotics and the invention therefore includes within its scope pharmaceutical compositions comprising an antibiotic compound in accordance with the invention adapted to use in human or veterinary medicine. Such compositions may be presented for use in conventional manner with the aid of any necessary pharmaceutical carriers or excipients.

The antibiotic compounds according to the invention may be formulated for injection and may be presented in unit dose form in ampoules, or in multi-dose containers, if necessary with an added preservative. The compositions may also take such forms as suspensions, solutions, or emulsions in oily or aqueous vehicles, and may contain formulatory agents such as suspending, stabilising and/or dispersing agents. Alternatively the active ingredient may be in powder form for reconstitution with a suitable vehicle, e.g. sterile, pyrogen-free water, before use.

If desired, such powder formulations may contain an appropriate non-toxic base in order to improve the water-solubility of the active ingredient and/or to ensure that when the powder is reconstituted with water, the pH of the resulting aqueous formulation is physiologically acceptable. Alternatively, the base may be present in the water with which the powder is reconstituted. The base may be, for example, an inorganic base such as sodium carbonate, sodium bicarbonate or sodium acetate, or an organic base such as lysine or lysine acetate.

The antibiotic compounds may also be formulated as 5 suppositories, e.g. containing conventional suppository bases such as cocoa butter or other glycerides.

For medication of the eyes or ears, the preparations may be formulated as individual capsules, in liquid or semi-solid form, or may be used as drops.

Compositions for veterinary medicine may, for example, be formulated as intramammary preparations in either long acting or quick-release bases.

The compositions may contain from 0.1% upwards, e.g. 0.1-99%, of the active material, depending on the _5 method of administration. When the compositions comprise dosage units, each unit .should preferably contain 50-1500 mg of the active ingredient. The dosage as employed for adult human treatment will preferably range from 500 to 6000 mg per day, depending on the route and frequency of administration. For example, in adult human treatment 1000 to 3000 mg per day administered intravenously or intramuscularly should normally suffice. In treating Pseudomonas infections higher daily doses may be required.

The antibiotic compounds according to the invention may be administered in combination with other therapeutic agents such as antibiotics, for example penicillins or other cephalosporins.

The following formulation illustrates how a compound according to the invention may be made up into a pharmaceutical composition.

Formulation - For Injection 5 Formula Per Vial (6R,7R)-7- [(Z)-2-(2-Aminothiazol-4-yl)-2-(1-carboxycyclobut-l-oxylmino)-acetamido]-3-trimethylaminoniomethyl-ceph3-em-4-carboxylate 500 mg Sodium carbonate, anhydrous 49 mg Method Blend the sterile cephalosporin antibiotic with sterile sodium carbonate under aseptic conditions. Fill aseptically into glass vials under a blanket of sterile nitrogen. Close the vials using rubber discs, or plugs, held in position by aluminium overseals, thereby preventing gaseous exchange or ingress of microorganisms. Reconstitute the product by dissolving in Water for Injections or other suitable sterile vehicle shortly before administration.

Claims (10)

1. Cephalosporin antibiotics of general formula a. b (wherein R and R , which may be the same or different, a b

2. Compounds as claimed in claim 1 wherein at least s b one of R and R represents a methyl or ethyl group. b 3. B 5 (wherein R and R are as defined in claim 1; R represents a carboxyl blocking group; and R is an amino or protected amino group) or with an acylating agent corres ponding thereto; (B) reacting a compound of formula (wherein R , R , R , B and the dotted line are as herein 7 7a before defined; R and R may independently represent hydrogen or a carboxyl blocking group; and X is a replaceable residue of a nucleophile) or a salt thereof with a tertiary amine of the formula (wherein R , R and R are as defined above); alkylating a compound of formula (V) or (C) carboxyl blocking groups with an alkylating agent serving to form a group of formula R 1 - CH„N® - R 2 2, 3 R 12 3 (wherein R , R and R are as defined above) at the 3position; whereafter if necessary and/or desired in each instance, any of the following reactions, in any appropriate sequence, are carried out:2 3 i) conversion of a Δ -isomer into the desired Δ isomer, ii) reduction of a compound wherein B is >S->0 to form a compound wherein B is >S, iii) conversion of a carboxyl group into a non-toxic salt or non-toxic metabolically labile ester function, and iv) removal of any carboxyl blocking and/or N-protecting groups. LO. A pharmaceutical composition for use in human or veterinary medicine comprising an antibiotic compound as claimed in any of claims 1 to 8 in association with a pharmaceutical carrier or excipient.

3. Compounds as claimed in claim 1 wherein R and R together with the carbon atom to which they are attached 15 form a C^ cycloalkylidene group. 4. -positions indicates that the compound is a ceph-2-em or ceph-3-em compound), or a salt or N-silyl derivative thereof or a corresponding compound having a group of Λ . Λ formula -COOR at the 4-position (where R is a hydrogen atom or a carboxyl blocking group) and having ai associated anion zP, with an acid of formula .6 C. COOH (III) 0. C.COOR

4. Compounds as claimed in any of the preceding claims 12 3 wherein R , R and R all represent methyl groups. 5. 11. A cephalosporin antibiotic according to claim 1, substantially as described herein by way of Example. 12. A process for the preparation of a cephalosporin antibiotic 4¼ Λι substantially as described herein by way of Example. t3. A Cejshalittjjffn-n I tofttn obtained Ly a process according to either of claims 9 and 12.

5. (6R,7R)-7-[(Z)-2-(2-Aminothiazol-4-yl)-2-(2carboxyprop-2-oxyimino) -’acetamido]-3-trimethylammonio20 methyl-ceph-3-em-4-carboxylate. 5 each represent a C^ alkyl group or R and R together with the carbon atom to which they are attached form a 12 3 C^ 7 cycloalkylidene group; and R , R and R , which may be the same or different, each represents a C^_^ alkyl group)and non-toxic salts and non-toxic metabolically 10 labile esters thereof.

6. The non-toxic salts of the compound of claim 5.

7. (6R,7R)-7-[(Z)-2-(2-Aminothiazol-4-yl)-2-(lcarboxycyclobut-l-oxyimino)-acetamido]-3-trimethylammoniomethy1-ceph-3-em-4-carboxylate·

8. The non-toxic salts of the compound of claim 7.

9. A process for the preparation of an antibiotic compound of general formula (I) as defined in claim 1 or a non-toxic salt or non-toxic metabolically labile ester thereof which comprises (A) acylating a compound of formula (II) B is >S or >S-^>0 and the dotted line bridging the 2-, 3- and

10. 14. A pharmaceutical composition containing as active ingredient a cfipha-losporin compound according to any of claims 1 to 8, 11 or 13.